Published on 29/11/2025

Automation/SCADA Controls in Closed Systems

Introduction to Closed Systems and Aseptic Controls

The pharmaceutical industry has seen a considerable shift toward the implementation of closed systems and single-use technologies, especially in biologics and advanced therapy medicinal products (ATMPs). These systems serve as a critical component in ensuring product sterility and compliance with aseptic controls outlined in regulatory guidelines such as Annex 1 from the European Medicines Agency (EMA). This article aims to provide a thorough, step-by-step guide for pharma professionals engaged in the validation of these automated processes.

As the complexity of biopharmaceutical manufacturing increases, so does the need for stringent validation processes. This tutorial will cover essential elements such as viral clearance validation, spiking studies, and the management of critical quality attributes (CQAs) inherent to these systems.

The Importance of Automation in Closed Systems

Automation technologies, including Supervisory Control and Data Acquisition (SCADA) systems, have emerged as integral parts of biopharmaceutical manufacturing. They enhance the consistency, accuracy, and efficiency of operations — all of which are pivotal in maintaining aseptic conditions. These systems not only streamline processes but also collect crucial data that can be used in compliance with regulations.

Moreover, closed systems reduce the risk of microbial contamination, which is paramount in the manufacturing of biologics and ATMPs. Introducing automation techniques helps in implementing robust cleaning regimes, monitoring processes in real-time, and consequently upholding the integrity of the product being manufactured.

Regulatory Compliance and Standards

When utilizing automation in closed systems, compliance with regulatory authorities such as the FDA, EMA, and MHRA is non-negotiable. For example, the FDA Process Validation guidelines highlight the necessity for comprehensive validation protocols that specify essential processes and controls tailored to the unique needs of your operations. These include managing risks associated with contamination, ensuring viral clearance, and conducting effective spiking studies to validate these controls.

Step 1: Identify Key Critical Quality Attributes (CQAs)

A critical first step in the validation process is identifying the key CQAs for your processes. CQAs can include potency, identity, and purity of the product. Understanding these parameters allows for a more focused validation strategy.

• Potency and Identity: Ensure the product exhibits its intended therapeutic effects, which are often defined through stringent biophysical and biochemical assays.
• Purity: Establish acceptable limits of contaminants, including residual DNA and host cell proteins.
• Chain of Identity (CoI) and Chain of Custody (CoC): Properly document the handling and transfer of product samples to ensure traceability throughout the manufacturing process.

Step 2: Design Comprehensive Viral Clearance Validation Studies

Viral contamination remains one of the most significant risks in biopharmaceutical manufacturing. Therefore, robust viral clearance validation studies are critical. These should be meticulously designed to demonstrate that your product and processes can effectively inactivate or remove potential viral pathogens.

Viral Clearance Strategy Development

To establish an effective viral clearance strategy, follow these guidelines:

• Spiking Studies: Conduct spiking studies wherein known quantities of virus are added to the manufacturing process. This will help assess the efficacy of your viral clearance measures.
• Process Mapping: Develop a detailed process map illustrating each step where viral contaminants could be introduced, including raw material handling and equipment assembly.
• Validation Protocol: Create a detailed validation protocol that accounts for variations in viral load, process parameters, and forms of viral clearance technologies used (e.g., filtration, chromatography).

Adhering to ICH Q5A(R2) will help guide the development of a stringent viral safety strategy by establishing a scientific foundation for these studies.

Step 3: Conducting Aseptic Process Validation

Aseptic processing is significant in ensuring the sterility of final products, particularly in biologics and ATMPs. Aseptic process validation should demonstrate that the methods employed consistently produce a sterile product. This includes extensive environmental monitoring, personnel training, and cleaning validation strategies.

Components of Aseptic Process Validation

The aseptic process validation should include the following components:

• Media Fill Studies: Perform media fill studies to simulate the aseptic filling process under controlled conditions to demonstrate that the filling operation can be conducted without contamination.
• Environmental Monitoring: Implement an environmental monitoring program that routinely evaluates airborne and surface contamination levels in the manufacturing environment.
• Personnel Gowning and Training: Ensure that all personnel involved in the aseptic process have undergone rigorous training and are compliant with gowning procedures to mitigate contamination risks.

Step 4: Tailoring PPQ and CPV for ATMPs

Process Performance Qualification (PPQ) and Continued Process Verification (CPV) are integral to maintaining process integrity and product quality over the lifecycle of ATMPs. Hence, they need tailored approaches suitable for the specific challenges presented by these complex products.

Developing a Tailored Approach

When customizing PPQ and CPV, consider the following:

• Flexibility in Process Parameters: Establish a robust framework that allows for variability in process parameters without compromising product quality.
• Ongoing Monitoring: Utilize SCADA systems for real-time data acquisition and monitoring to facilitate continuous improvement and quick response to any anomalies detected during production.
• Risk Assessment: Conduct regular risk assessments to identify potential points of failure that may affect product quality.

Incorporating these elements into your PPQ and CPV strategy ensures a solid foundation for the ongoing compliance and quality assurance of ATMP manufacturing.

Step 5: Documentation and Regulatory Submission

Finally, comprehensive documentation processes will substantiate your validation efforts when submitting to regulatory authorities. Accurate and thorough documentation allows for transparency and traceability of all actions taken during the validation process.

• Validation Reports: Prepare detailed validation reports that summarize your studies, methodologies, results, and conclusions.
• Change Control Documentation: Establish a change control process for any modifications made to processes, equipment, or materials.
• Regulatory Submission Packages: Ensure your documentation is compliant with the submission requirements of regulatory bodies such as the FDA, EMA, and MHRA.

Conclusion

Automation and SCADA controls in closed systems play a crucial role in the validation of biologics and advanced therapy medicinal products. By following this step-by-step guide, pharmaceutical professionals can ensure that their processes meet stringent regulatory standards while minimizing the risks associated with contamination and variability. From identifying critical quality attributes to thorough validation strategies for viral clearance and aseptic processing, each step is imperative in maintaining the high standards set forth by regulatory authorities.

As the industry evolves, it is essential to continuously refine validation processes, incorporate advanced technologies, and ensure compliance with the evolving regulatory landscape. With careful planning and dedicated execution of these protocols, the path to quality assurance in the manufacturing of closed systems and single-use technologies will become increasingly clear.